On Air Now

Current Show

Jerry Bader   8:30 AM - 11:00 AM

Text "JBSHOW" to 79489 and get updates from me. Email me at: jerrybadershow@mwcradio.com

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 1360 AM Northeast, WI 97.5 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
70° Feels Like: 70°
Wind: NW 7 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Today

Scattered Thunderstorms 75°

Tonight

Thunderstorms Early 55°

Tomorrow

Mostly Sunny 75°

Alerts

Roche's Avastin misses key data point in brain cancer study

A logo of Swiss pharmaceutical company Roche is pictured in front of a company's building in Rotkreuz, April 12, 2012. REUTERS/Michael Buhol
A logo of Swiss pharmaceutical company Roche is pictured in front of a company's building in Rotkreuz, April 12, 2012. REUTERS/Michael Buhol

ZURICH (Reuters) - Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the company said on Saturday.

The Phase III AVAglio study presented at the Society for Neuro-Oncology congress in Washington on Saturday showed Avastin, combined with radiation and chemotherapy, reduced the risk of cancer worsening or death, the Basel-based drugmaker said in a news release.

But the drug did not reach statistical significance in overall survival, a key data point. Further data are expected next year, Roche said.

"The interim results for overall survival (OS), the other co-primary endpoint, did not reach statistical significance," the company said in the statement.

Earlier data from the study published in August showed Avastin significantly extended progression-free survival of people with an aggressive form of brain cancer.

Avastin is Roche's third-biggest seller and is approved to treat several types of cancer, including breast, kidney, colorectal and ovarian cancers.

(Reporting by Katharina Bart and Caroline Copley; editing by Jason Webb)

Comments